LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,254
تعداد مقالات11,420
تعداد مشاهده مقاله81,782,919
تعداد دریافت فایل اصل مقاله120,940,753
Amoozgar, Hamid, Hosseini, Hossein, Mohammadi, Hamid, Fereidoonnezhad, Behrooz, Eynbeygui, Mehdi, Arghavani, Jamal, Zare, Afshin, Mehdizadegan, Nima, Edraki, Mohammad Reza, Naghshzan, Amir, Abedi, Elham, Khorraminejad-Shirazi, Mohammadhossein. (1404). Innovating Patent Ductus Arteriosus Closure: Preclinical Evaluation of the First Iranian-Developed Nitinol Occluder in a Sheep Model. سامانه مدیریت نشریات علمی, 51(2), 118-125. doi: 10.30476/ijms.2025.107171.4151
Hamid Amoozgar; Hossein Hosseini; Hamid Mohammadi; Behrooz Fereidoonnezhad; Mehdi Eynbeygui; Jamal Arghavani; Afshin Zare; Nima Mehdizadegan; Mohammad Reza Edraki; Amir Naghshzan; Elham Abedi; Mohammadhossein Khorraminejad-Shirazi. "Innovating Patent Ductus Arteriosus Closure: Preclinical Evaluation of the First Iranian-Developed Nitinol Occluder in a Sheep Model". سامانه مدیریت نشریات علمی, 51, 2, 1404, 118-125. doi: 10.30476/ijms.2025.107171.4151
Amoozgar, Hamid, Hosseini, Hossein, Mohammadi, Hamid, Fereidoonnezhad, Behrooz, Eynbeygui, Mehdi, Arghavani, Jamal, Zare, Afshin, Mehdizadegan, Nima, Edraki, Mohammad Reza, Naghshzan, Amir, Abedi, Elham, Khorraminejad-Shirazi, Mohammadhossein. (1404). 'Innovating Patent Ductus Arteriosus Closure: Preclinical Evaluation of the First Iranian-Developed Nitinol Occluder in a Sheep Model', سامانه مدیریت نشریات علمی, 51(2), pp. 118-125. doi: 10.30476/ijms.2025.107171.4151
Amoozgar, Hamid, Hosseini, Hossein, Mohammadi, Hamid, Fereidoonnezhad, Behrooz, Eynbeygui, Mehdi, Arghavani, Jamal, Zare, Afshin, Mehdizadegan, Nima, Edraki, Mohammad Reza, Naghshzan, Amir, Abedi, Elham, Khorraminejad-Shirazi, Mohammadhossein. Innovating Patent Ductus Arteriosus Closure: Preclinical Evaluation of the First Iranian-Developed Nitinol Occluder in a Sheep Model. سامانه مدیریت نشریات علمی, 1404; 51(2): 118-125. doi: 10.30476/ijms.2025.107171.4151

Innovating Patent Ductus Arteriosus Closure: Preclinical Evaluation of the First Iranian-Developed Nitinol Occluder in a Sheep Model

Iranian Journal of Medical Sciences
مقاله 4، دوره 51، شماره 2، اردیبهشت 2026، صفحه 118-125    اصل مقاله (1.83 M)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2025.107171.4151
نویسندگان
Hamid Amoozgar1؛ Hossein Hosseini2؛ Hamid Mohammadi* 3؛ Behrooz Fereidoonnezhad4؛ Mehdi Eynbeygui5؛ Jamal Arghavani5؛ Afshin Zare6؛ Nima Mehdizadegan3؛ Mohammad Reza Edraki3؛ Amir Naghshzan3؛ Elham Abedi7؛ Mohammadhossein Khorraminejad-Shirazi8، 9، 10
1Neonatal Research Center, Department of Pediatrics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
3Department of Pediatrics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
4Department of Biomechanical Engineering, Delft University of Technology, Delft, 2628 CD, Netherlands
5Department of Mechanical Engineering, Sharif University of Technology, Tehran, Iran
6Department of Surgery, Shiraz University of Medical Sciences, Shiraz, Iran
7Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
8Zoonoses Research Center, Jahrom University of Medical Sciences, Jahrom, Iran
9Department of Pathology, School of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran
10Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: Patent ductus arteriosus (PDA) is a congenital defect characterized by abnormal blood flow between the aorta and pulmonary artery. Existing closure devices, such as the Amplatzer Duct Occluder (ADO), face challenges with affordability, biocompatibility, and anatomical adaptability. This study evaluates the safety and feasibility of a novel nitinol-based PDA occluder, the first developed sample in Iran, designed to enhance biocompatibility, reduce thrombogenicity, and improve durability.
Methods: This preclinical study was conducted in 2024 at the Large Animal Research Laboratory, Shiraz University of Medical Sciences, Shiraz, Iran. The occluder was fabricated from custom-made nitinol wires braided into a 72-wire conical mesh, ensuring flexibility and durability. Deployment was tested in a sheep model via femoral and pulmonary artery access. Post-procedure evaluations included angiography, clinical monitoring, and histopathological analyses to assess tissue integration, thrombogenicity, and biocompatibility.
Results: The device was successfully deployed in two target sites with stable positioning and no procedural complications. Angiographic imaging confirmed vessel patency, even in an artery with a size mismatch. The animal exhibited no adverse outcomes, maintaining normal pulses and activity over a three-month follow-up. Post-mortem analysis revealed secure device placement without migration, perforation, or aneurysm. Histopathological findings demonstrated mild inflammation, neointimal formation, and re-endothelialization, with no significant thrombus or granuloma, indicating excellent biocompatibility.
Conclusion: This study provides preliminary evidence supporting the feasibility, safety, and biocompatibility of the Iranian-developed PDA occluder. These findings suggest the device may serve as a viable, cost-effective alternative for PDA closure, addressing device shortages and advancing regional medical technology.

تازه های تحقیق

Hamid Amoozgar (Google Scholar)

Hamid Mohammadi (Google Scholar)

کلیدواژه‌ها
Patent ductus arteriosus؛ Nitinol؛ Thrombosis؛ Biocompatible materials؛ Sheep
مراجع
  1. Bass JL, Wilson N. Transcatheter occlusion of the patent ductus arteriosus in infants: experimental testing of a new Amplatzer device. Catheter Cardiovasc Interv. 2014;83:250-5. doi: 10.1002/ccd.22931. PubMed PMID: 24446324.
  2. Bruckheimer E, Steiner K, Barak-Corren Y, Slanovic L, Levinzon M, Lowenthal A, et al. The Amplatzer duct occluder (ADOII) and Piccolo devices for patent ductus arteriosus closure: a large single institution series. Front Cardiovasc Med. 2023;10:1158227. doi: 10.3389/fcvm.2023.1158227. PubMed PMID: 37215550; PubMed Central PMCID: PMC10193946.
  3. Jalal Z, Seguela PE, Baruteau AE, Benoist D, Bernus O, Villemain O, et al. Role of animal models for percutaneous atrial septal defect closure. J Thorac Dis. 2018;10:S2966-S74. doi: 10.21037/jtd.2018.07.119. PubMed PMID: 30305957; PubMed Central PMCID: PMC6174152.
  4. Yildiz K, Narin N, Oksuz S, Ozdemir R, Pamukcu O, Baykan A, et al. Safety and efficacy of Amplatzer duct occluder II and konar-MF VSD occluder in the closure of perimembranous ventricular septal defects in children weighing less than 10 kg. Front Cardiovasc Med. 2023;10:1255808. doi: 10.3389/fcvm.2023.1255808. PubMed PMID: 38094116; PubMed Central PMCID: PMC10716692.
  5. Santhanam H, Yang L, Chen Z, Tai BC, Rajgor DD, Quek SC. A meta-analysis of transcatheter device closure of perimembranous ventricular septal defect. Int J Cardiol. 2018;254:75-83. doi: 10.1016/j.ijcard.2017.12.011. PubMed PMID: 29273241.
  6. Liu J, Wang Z, Gao L, Tan HL, Zheng Q, Zhang ML. A Large Institutional Study on Outcomes and Complications after Transcatheter Closure of a Perimembranous-Type Ventricular Septal Defect in 890 Cases. Acta Cardiol Sin. 2013;29:271-6. PubMed PMID: 27122716; PubMed Central PMCID: PMC4804839.
  7. Cen H, Peng B, Li J, Chen S, Sun P. Efficacy and safety of the Amplatzer Duct Occluder II for ventricular septal defect closure: a meta-analysis. Kardiol Pol. 2021;79:401-9. doi: 10.33963/KP.15762. PubMed PMID: 33506659.
  8. Iskander B, Anwer F, Oliveri F, Fotios K, Panday P, Arcia Franchini AP, et al. Amplatzer Patent Foramen Ovale Occluder Device-Related Complications. Cureus. 2022;14:e23756. doi: 10.7759/cureus.23756. PubMed PMID: 35402119; PubMed Central PMCID: PMC8980243.
  9. Fiszer R, Chojnicki M, Szkutnik M, Haponiuk I, Chodor B, Bialkowski J. Are the AMPLATZER Duct Occluder II Additional Sizes devices dedicated only for smaller children? EuroIntervention. 2017;12:2100-3. doi: 10.4244/EIJ-D-15-00238. PubMed PMID: 27867138.
  10. Rodriguez Ogando A, Ballesteros Tejerizo F, Blanco Bravo D, Sanchez Luna M, Zunzunegui Martinez JL. Transcatheter Occlusion of Patent Ductus Arteriosus in Preterm Infants Weighing Less Than 2 kg With the Amplatzer Duct Occluder II Additional Sizes Device. Rev Esp Cardiol (Engl Ed). 2018;71:865-6. doi: 10.1016/j.rec.2017.08.014. PubMed PMID: 28916428.
  11. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington: National Academies Press; 2011.
  12. Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020;18:e3000410. doi: 10.1371/journal.pbio.3000410. PubMed PMID: 32663219; PubMed Central PMCID: PMC7360023
  13. Nour A, Abdelrazik Y, Huessin S, Kamel H. Safety and efficacy of percutaneous patent ductus arteriosus closure: a multicenter Egyptian experience. Egypt Heart J. 2022;74:14. doi: 10.1186/s43044-022-00251-3. PubMed PMID: 35244792; PubMed Central PMCID: PMC8897530.
  14. Portillo E, Mackin A, Hendrix PK, Boyle C, Chrestman L. Comparison of the modified Seldinger and through-the-needle jugular catheter placement techniques in the dog. J Vet Emerg Crit Care (San Antonio). 2006;16:88-95. doi: 10.1111/j.1476-4431.2006.00147.x.
  15. Sideris G, Magkoutis N, Voicu S, Kang C, Bonneau M, Yannopoulos D, et al. A novel experimental thrombotic myocardial infarction and primary angioplasty model in swine. EuroIntervention. 2019;14:e1843-e51. doi: 10.4244/EIJ-D-17-00763. PubMed PMID: 29901442.
  16. Boehm W, Emmel M, Sreeram N. The Amplatzer duct occluder for PDA closure: indications, technique of implantation and clinical outcome. Images Paediatr Cardiol. 2007;9:16-26. PubMed PMID: 22368670; PubMed Central PMCID: PMC3232577.
  17. Pepeta L, Dippenaar A. Ductal closure using the Amplatzer duct occluder type two: experience in Port Elizabeth hospital complex, South Africa: cardiovascular topic. Cardiovasc J Afr. 2013;24:202-7. doi: 10.5830/CVJA-2013-033. PubMed PMID: 23812377; PubMed Central PMCID: PMC4986386.
  18. Kiani AK, Pheby D, Henehan G, Brown R, Sieving P, Sykora P, et al. Ethical considerations regarding animal experimentation. J Prev Med Hyg. 2022;63:E255-E66. doi: 10.15167/2421-4248/jpmh2022.63.2S3.2768. PubMed PMID: 36479489; PubMed Central PMCID: PMC9710398.
آمار
تعداد مشاهده مقاله: 127
تعداد دریافت فایل اصل مقاله: 217


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب